EMA fol­lows FDA to ap­prove Roche's Tecen­triq com­bo for front­line use in triple neg­a­tive breast can­cer

Months af­ter Roche se­cured US ap­proval for its check­point in­hibitor Tecen­triq, in com­bi­na­tion with Cel­gene’s Abrax­ane, for front­line use in an ag­gres­sive, tough-to-treat sub­group of breast can­cer pa­tients — the EU has fol­lowed suit.

On Thurs­day, the Swiss gi­ant said the Tecen­triq com­bo is the first can­cer im­munother­a­py reg­i­men to be cleared by Eu­ro­pean reg­u­la­tors for triple-neg­a­tive breast can­cer (TNBC).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.